DOCSLIB.ORG

NASA Armstrong X-Press, March 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NASA Armstrong X-Press, March 2019 National Aeronautics and Space Administration Volume 61 Number 2 March 2019 NASA, center budgets solid Bridenstine mentions X-57, X-59 in opening remarks By Jay Levine biggest portions: $129.8 million, X-Press editor $62.6 million and $69 million, The Trump Administration’s respectively. Rounding out the proposed 2020 NASA budget was budget are $3.9 million for released March 11 and it’s good news Exploration Technology, $0.8 for the agency and for Armstrong. million for Deep Space Exploration “At $21 billion, this budget Systems, $0.2 million for Low Earth represents a nearly 6 percent increase Orbit and Spaceflight Operations over last year’s request and comes at a and $27.4 million for Construction time of constrained resources across and Environmental Compliance the federal government,” said NASA and Restoration. Administrator Jim Bridenstine. “It The Science funding supports also is a huge vote of confidence for extended operations for the all of the agency’s hard work and airborne Stratospheric Observatory dedication.” for Infrared Astronomy (SOFIA), “We will go to the Moon with AFRC2019-0047-16 NASA/Lauren Hughes a partnership with the German innovative new technologies and Armstrong Deputy Director Patrick Stoliker discusses the center’s proposed Aerospace Center. Armstrong systems to explore more locations budget. operates the airborne astronomical across the lunar surface than ever observatory that is capable before,” he said. “This time, when and the launch of the James pushing technology and regulatory of observing a wide variety we go to the Moon, we will stay. We Webb Space Telescope. Planning boundaries. The X-59 could lead of astronomical objects and will use what we learn as we move and developing the first round- to commercial supersonic travel, phenomena. forward to the Moon to take the trip mission to Mars with a currently prohibited by law, that The Science budget also supports next giant leap – sending astronauts sample return also is under way. could greatly reduce travel times for center Airborne Science platforms to Mars.” Closer to Earth, the Aeronautics coast-to-coast travel, while the X-57 that are set to support the Earth NASA also will continue ushering proposed budget is $667 million, could reduce noise, emissions and Venture Suborbitals-3 mission. in a new era of human spaceflight up more than $31 million. Included regional travel costs to open new Armstrong operates a fleet of as American astronauts are is funding for the X-57 distributed economic possibilities. scientific aircraft supporting remote launched on American rockets from electric propulsion aircraft and Armstrong’s proposed 2020 sensing observations for Earth American soil for the first time since construction of the experimental budget is $293.7 million, which science. 2011. The Space Launch System, supersonic X-59 aircraft. Theis up from last year overall, and Deep Space Exploration Systems Orion spacecraft, and Gateway will budget also accelerates research in employment and the center’s core include the Ascent Abort-2 Flight continue to be the base for deep urban air mobility and completes work are stable, said Patrick Stoliker, Test in 2019 and Exploration space exploration. technology demonstrations to Armstrong deputy director. Technology funding is stable. That Additional goals include NASA integrate larger UAS into the NAS. Of the proposed $293.7 million area includes Armstrong’s role as the studying the Earth and the Sun, In fact, Bridenstine began his Armstrong budget, Aeronautics, Level 2 Program Office for the Flight revealing the unknown with presentation with mentions of Science and Safety, Security and missions to Jupiter’s moon Europa the agency’s two new X-planes Mission Services comprise the Budget, page 4 www.nasa.gov/ X-Press March 2019 Air shows return in 2020 First the good news: there will will showcase this amazing location be two air shows in the Antelope as the primary place on the planet Valley in 2020. Now the bad news: for aerospace expertise, innovation no air shows in 2019. and partnerships,” Teichert said. The Los Angeles County Air “It will also provide an incredible Show (LACAS) Board of Directors opportunity to inspire, encourage and Edwards Air Force Base senior and educate adults and children leadership are working to complete alike while demonstrating what we a multi-year partnership to have air at Edwards provide to the warfighter. shows within the Aerospace Valley. We are proud to be a key part of the The partnership includes resuming Aerospace Valley and to work with air shows at Edwards Air Force Base the superb team at the LACAS.” in 2020, which have not occurred Los Angeles County Air Show since 2009. Inc. will host key community The October 2019 air show dates events this year, including a large for the LACAS Gen. William J. Fox interactive Aerospace Valley STEM AFRC2018-0056-062 NASA/Ken Ulbrich Air Field in Lancaster moved to exhibition at the Antelope Valley March 2020 to accommodate the Armstrong pilots Stu Broce, Greg Nelson and Tim Williams sign autographs at Fair Aug. 16-25. schedeule of the U.S. Navy Blue the 2018 Los Angeles County Air Show at the Gen. William J. Fox Airfield. “Our commitment to inspire and Angels flight demonstration team. connect our local youth to STEM An air show is set for Edwards Air stakeholders.” • Oct. 14-16, 2022 at Edwards has not wavered,” said VanKirk. Force Base in October 2020 featuring The air show dates for 2020 are: Air Force Base “In 2019, along with many of our the U.S. Air Force Thunderbirds. • March 21-22, 2020, at Fox “Team Edwards is very excited air show partners, we will host an “The Blue Angels communicated Airfield, Lancaster, featuring theto move forward with our LACAS impressive, interactive Aerospace their desire to kick off their 2020 U.S. Navy Blue Angels partners to bring an air show back Valley STEM event that is second season at the LACAS at Fox • Oct. 10-11, 2020, at Edwards to Edwards Air Force Base – the to none at this year’s Antelope Valley Field in Lancaster,” said Mike Air Force Base featuring the U.S. center of the aerospace testing Fair. This will be a great way to VanKirk, LACAS president. “After Air Force Thunderbirds. universe,” said Brig. Gen. E. engage both young and seasoned air careful consideration, the LACAS The future plan is to rotate bi- John Teichert, 412th Test Wing show fans. Having the opportunity board of directors agreed that annual shows starting in 2021 with commander. to have an impressive footprint at accommodating the Blue Angels the following preliminary dates: “Our partnership will establish an iconic event like the AV Fair is schedule is in the best interest of • Oct. 15-17, 2021 at Fox a one-of-a-kind, world-class invaluable to raise awareness for our our air show, our fans and our key Airfield, Lancaster. Aerospace Valley Air Show that future shows.” Super Guppy visits for its maintenance By Kate Squires Armstrong Public Affairs NASA’s B-377SGT Super Guppy Turbine cargo aircraft, operated by NASA’s Johnson Space Center, arrived at Armstrong’s Building 703 in Palmdale, April 1 to continue its phase maintenance period requiring hangar support. The whale-like aircraft transports oversized parts, such as International Space Station modules, Orion heat shields, Orion crew modules, the Space Launch System Service Module Adapter, and other oversized aerospace hardware across the U.S. for the agency. Phase maintenance checks are periodic inspections that have to be performed on all commercial and civil aircraft after a certain amount of time or usage. While the Super Guppy normally undergoes such maintenance at Ellington Field near the Johnson Space Flight Center facilities in Houston and the El Paso Forward Operating Location at El Paso International AFRC2019-0062-01 NASA/Ken Ulbrich Super Guppy, page 3 NASA’s Super Guppy aircraft arrives for maintenance at Building 703. X-Press March 2019 News at NASA ISS research looking at Parkinson’s Parkinson’s disease affects more than 5 million people on Earth. Research on the International Space Station could provide insight into this chronic neurodegenerative disease and help scientists find ways to treat and prevent it. The investigation, Crystallization of LRRK2 Under Microgravity Conditions-2 (CASIS PCG 16), grows protein crystals of Leucine-rich repeat kinase 2 (LRRK2) on the space station. A kinase is an enzyme NASA/David C. Bowman that adds phosphate groups to other molecules as part of the DAWN readied for DC-8 mission body’s metabolic processes. People with Parkinson’s disease Electronics technician Anna Noe makes final checks to the Doppler Aerosol Wind Lidar (DAWN) before it begins a experience increased function cross-country road trip for use in an upcoming airborne science campaign. Noe is pictured here from the underside of of LRRK2, and genetic studies the instrument looking through the exit optical window. Developed at NASA’s Langley Research Center in Virginia, link mutations in the LRRK2 DAWN uses laser pulses to take highly accurate measurements of vector wind speed and direction. In the upcoming gene to an increased risk of campaign, which will be based from Armstrong, scientists will use DAWN to validate measurements from Atmospheric developing Parkinson’s disease. Dynamics Mission Aeolus (ADM-Aeolus), a European Space Agency satellite that profiles wind speeds across the globe. Medications that inhibit LRRK2 ADM-Aeolus launched in August 2018. Researchers believe data from the satellite will help improve the accuracy of are in development, but without weather forecasts. Validation flights aboard the Armstrong DC-8 flying laboratory are scheduled to begin April 15. knowing the precise structure of Langley scientist Michael Kavaya is the principal investigator for DAWN.
Load more

Recommended publications
  • LRRK2 at the Crossroad of Aging and Parkinson's Disease
    G C A T T A C G G C A T genes Review LRRK2 at the Crossroad of Aging and Parkinson’s Disease Eun-Mi Hur 1 and Byoung Dae Lee 2,3,* 1 Department of Neuroscience, College of Veterinary Medicine, Research Institute for Veterinary Science and BK21 Four Future Veterinary Medicine Leading Education & Research Center, Seoul National University, Seoul 08826, Korea; [email protected] 2 Department of Physiology, Kyung Hee University School of Medicine, Seoul 02447, Korea 3 Department of Neuroscience, Kyung Hee University, Seoul 02447, Korea * Correspondence: [email protected]; Tel.: +82-2-961-9381 Abstract: Parkinson’s disease (PD) is a heterogeneous neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the widespread occurrence of proteinaceous inclusions known as Lewy bodies and Lewy neurites. The etiology of PD is still far from clear, but aging has been considered as the highest risk factor influencing the clinical presentations and the progression of PD. Accumulating evidence suggests that aging and PD induce common changes in multiple cellular functions, including redox imbalance, mitochondria dysfunction, and impaired proteostasis. Age-dependent deteriorations in cellular dysfunction may predispose individuals to PD, and cellular damages caused by genetic and/or environmental risk factors of PD may be exaggerated by aging. Mutations in the LRRK2 gene cause late-onset, autosomal dominant PD and comprise the most common genetic causes of both familial and sporadic PD. LRRK2-linked PD patients show clinical and pathological features indistinguishable from idiopathic PD patients. Here, we review cellular dysfunctions shared by aging and PD-associated LRRK2 mutations and discuss how the interplay between the two might play a role in PD pathologies.
    [Show full text]
  • Pleiotropic Effects for Parkin and LRRK2 in Leprosy Type-1 Reactions and Parkinson’S Disease
    Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson’s disease Vinicius M. Favaa,b,1,2, Yong Zhong Xua,b, Guillaume Lettrec,d, Nguyen Van Thuce, Marianna Orlovaa,b, Vu Hong Thaie, Shao Taof,g, Nathalie Croteauh, Mohamed A. Eldeebi, Emma J. MacDougalli, Geison Cambrij, Ramanuj Lahirik, Linda Adamsk, Edward A. Foni, Jean-François Trempeh, Aurélie Cobatl,m, Alexandre Alcaïsl,m, Laurent Abell,m,n, and Erwin Schurra,b,o,1,2 aProgram in Infectious Diseases and Immunity in Global Health, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada H4A3J1; bMcGill International TB Centre, Montreal, QC, Canada H4A 3J1; cMontreal Heart Institute, Montreal, QC, Canada H1T 1C8; dDepartment of Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada H3T 1J4; eHospital for Dermato-Venereology, District 3, Ho Chi Minh City, Vietnam; fDivision of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada H3G 2M1; gThe Translational Research in Respiratory Diseases Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada H4A 3J1; hCentre for Structural Biology, Department of Pharmacology & Therapeutics, McGill University, Montreal, QC, Canada H3G 1Y6; iMcGill Parkinson Program, Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4; jGraduate Program in Health Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, PR, 80215-901, Brazil; kNational Hansen’s Disease Program, Health Resources and Services Administration, Baton Rouge, LA 70803; lLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale 1163, 75015 Paris, France; mImagine Institute, Paris Descartes-Sorbonne Paris Cité University, 75015 Paris, France; nSt.
    [Show full text]
  • LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1
    This is a repository copy of Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/130583/ Version: Accepted Version Article: Williamson, Douglas S., Smith, Garrick P., Acheson-Dossang, Pamela et al. (20 more authors) (2017) Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). JOURNAL OF MEDICINAL CHEMISTRY. pp. 8945-8962. ISSN 0022-2623 https://doi.org/10.1021/acs.jmedchem.7b01186 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Design of LRRK2 inhibitors using a CHK1-derived crystallographic surrogate Douglas S. Williamson,†* Garrick P. Smith,‡ Pamela Acheson-Dossang,† Simon T. Bedford,† Victoria Chell,† I-Jen Chen,† Justus C. A. Daechsel,‡ Zoe Daniels,† Laurent David,‡ Pawel Dokurno,† Morten Hentzer,‡ Martin C. Herzig,‡ Roderick E.
    [Show full text]
  • ISS National Lab Q1FY19 Report Quarterly Report for the Period October 1 – December 31, 2018
    NASAWATCH.COM ISS National Lab Q1FY19 Report Quarterly Report for the Period October 1 – December 31, 2018 Contents Q1FY19 Metrics ........................................................................................................................................... 2 Key Portfolio Data Charts ............................................................................................................................. 6 Program Successes ...................................................................................................................................... 6 In-Orbit Activities ........................................................................................................................................ 7 Research Solicitations in Progress ................................................................................................................ 7 Appendix .................................................................................................................................................... 8 Authorized for submission to NASA by: _______________________________ Print Name _______________ Signature ________________________________________________________ 1 NASAWATCH.COM NASAWATCH.COM ISS National Lab Q1FY19 Report Q1FY19 Metrics SECURE STRATEGIC FLIGHT PROJECTS: Generate significant, impactful, and measurable demand from customers that recognize value of the ISS National Lab as an innovation platform TARGET ACTUAL Q1 ACTUAL Q2 ACTUAL Q3 ACTUAL Q4 YTD FY19 FY19 ISS National Lab payloads manifested
    [Show full text]
  • Genes Implicated in Familial Parkinson's Disease Provide a Dual
    International Journal of Molecular Sciences Review Genes Implicated in Familial Parkinson’s Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage Rafael Franco 1,2,† , Rafael Rivas-Santisteban 1,2,† , Gemma Navarro 2,3,† , Annalisa Pinna 4,*,† and Irene Reyes-Resina 1,†,‡ 1 Department Biochemistry and Molecular Biomedicine, University of Barcelona, 08028 Barcelona, Spain; [email protected] (R.F.); [email protected] (R.R.-S.); [email protected] (I.R.-R.) 2 Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Instituto de Salud Carlos III, 28031 Madrid, Spain; [email protected] 3 Department Biochemistry and Physiology, School of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain 4 National Research Council of Italy (CNR), Neuroscience Institute–Cagliari, Cittadella Universitaria, Blocco A, SP 8, Km 0.700, 09042 Monserrato (CA), Italy * Correspondence: [email protected] † These authors contributed equally to this work. ‡ Current address: RG Neuroplasticity, Leibniz Institute for Neurobiology, Brenneckestr 6, 39118 Magdeburg, Germany. Abstract: The mechanism of nigral dopaminergic neuronal degeneration in Parkinson’s disease (PD) Citation: Franco, R.; Rivas- is unknown. One of the pathological characteristics of the disease is the deposition of α-synuclein Santisteban, R.; Navarro, G.; Pinna, (α-syn) that occurs in the brain from both familial and sporadic PD patients. This paper constitutes a A.; Reyes-Resina, I. Genes Implicated narrative review that takes advantage of information related to genes (SNCA, LRRK2, GBA, UCHL1, in Familial Parkinson’s Disease VPS35, PRKN, PINK1, ATP13A2, PLA2G6, DNAJC6, SYNJ1, DJ-1/PARK7 and FBXO7) involved in Provide a Dual Picture of Nigral familial cases of Parkinson’s disease (PD) to explore their usefulness in deciphering the origin of Dopaminergic Neurodegeneration dopaminergic denervation in many types of PD.
    [Show full text]
  • Structural Model of the Dimeric Parkinson's Protein LRRK2
    Structural model of the dimeric Parkinson’s protein PNAS PLUS LRRK2 reveals a compact architecture involving distant interdomain contacts Giambattista Guaitolia,b,1, Francesco Raimondic,d,1, Bernd K. Gilsbacha,e,f,1, Yacob Gómez-Llorenteg,1, Egon Deyaerth,i,1, Fabiana Renzig, Xianting Lij, Adam Schaffnerg,j, Pravin Kumar Ankush Jagtapk,l, Karsten Boldtb, Felix von Zweydorfa,b, Katja Gotthardtf, Donald D. Lorimerm, Zhenyu Yuej, Alex Burginn, Nebojsa Janjico, Michael Sattlerk,l, Wim Verséesh,i, SEE COMMENTARY Marius Ueffingb,2, Iban Ubarretxena-Belandiag,2,3, Arjan Kortholte,2,3, and Christian Johannes Gloecknera,b,2,3 aGerman Center for Neurodegenerative Diseases, 72076 Tübingen, Germany; bCenter for Ophthalmology, Institute for Ophthalmic Research, Eberhard Karls University, 72076 Tübingen, Germany; cDepartment of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; dCell Networks, University of Heidelberg, 69120 Heidelberg, Germany; eDepartment of Cell Biochemistry, University of Groningen, Groningen 9747 AG, The Netherlands; fStructural Biology Group, Max Planck Institute for Molecular Physiology, 44227 Dortmund, Germany; gDepartment of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029; hStructural Biology Brussels, Vrije Universiteit Brussel, 1050 Brussels, Belgium; iVlaams Instituut voor Biotechnologie, Structural Biology Research Center, Vrije Universiteit Brussel, 1050 Brussels, Belgium; jDepartments of Neurology and Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029; kCenter for Integrated Protein Science Munich at Department of Chemistry, Technische Universität München, 85747 Garching, Germany; lInstitute of Structural Biology, Helmholtz Zentrum München, 85764 Munich, Germany; mBeryllium Discovery Corporation, Bainbridge Island, WA 98110; nBroad Institute, Cambridge, MA 02142; and oSomaLogic, Boulder, CO 80301 Edited by Quyen Q.
    [Show full text]
  • LRRK2 GENETICS and EXPRESSION in the PARKINSONIAN BRAIN Thesis Submitted in Fulfilment of the Degree of Doctor of Philosophy
    LRRK2 GENETICS AND EXPRESSION IN THE PARKINSONIAN BRAIN Thesis submitted in fulfilment of the degree of Doctor of Philosophy 2010 Queen Square Brain Bank, Department of Molecular Neuroscience, Institute of Neurology & Institute of Human Genetics and Health, University College London Simone Sharma Declaration I hereby declare that the work described in this thesis is solely that of the author, unless stated otherwise in the text. None of the work has been submitted for any other qualification at this or any other university. Simone Sharma Abstract Mutations in LRRK2 have been established as a common genetic cause of Parkinson’s disease (PD). Variation in gene expression of PARK loci has previously been demonstrated in PD pathogenesis, although it has not been described in detail for LRRK2 expression in the human brain. This study further elucidates the role of LRRK2 in development of PD by describing an investigation into the role of LRRK2 genetics and expression in the human brain. The G2019S mutation is a common LRRK2 mutation that exhibits a clinical and pathological phenotype indistinguishable from idiopathic PD. Thus, the study of G2019S mutation is a recurrent theme. The frequency of G2019S was estimated in unaffected subjects that lived or shared a cultural heritage to the predicted founding populations of the mutation, and was found not to be common in these populations. Morphological analysis revealed a ubiquitous expression for LRRK2 mRNA and protein in the human brain. In-situ hybridisation data suggests that LRRK2 mRNA is present as a low copy number mRNA in the human brain. A semi-quantitative analysis of LRRK2 immunohistochemistry revealed extensive regional variation in the LRRK2 protein levels, although the weakest immunoreactivity was consistently identified in the nigrostriatal dopamine region.
    [Show full text]
  • Comprehensive Analysis of the LRRK2 Gene in Sixty Families with Parkinson’S Disease
    European Journal of Human Genetics (2006) 14, 322–331 & 2006 Nature Publishing Group All rights reserved 1018-4813/06 $30.00 www.nature.com/ejhg ARTICLE Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease Alessio Di Fonzo1,25, Cristina Tassorelli2, Michele De Mari3, Hsin F. Chien4, Joaquim Ferreira5, Christan F. Rohe´1, Giulio Riboldazzi6, Angelo Antonini7, Gianni Albani8, Alessandro Mauro8,9, Roberto Marconi10, Giovanni Abbruzzese11, Leonardo Lopiano9, Emiliana Fincati12, Marco Guidi13, Paolo Marini14, Fabrizio Stocchi15, Marco Onofrj16, Vincenzo Toni17, Michele Tinazzi18, Giovanni Fabbrini19, Paolo Lamberti3, Nicola Vanacore20, Giuseppe Meco19, Petra Leitner21, Ryan J. Uitti22, Zbigniew K. Wszolek22, Thomas Gasser21, Erik J. Simons23, Guido J. Breedveld1, Stefano Goldwurm7, Gianni Pezzoli7, Cristina Sampaio5, Egberto Barbosa4, Emilia Martignoni24,26 Ben A. Oostra1, Vincenzo Bonifati*,1,19, and The Italian Parkinson Genetics Network27 1Department of Clinical Genetics, Erasmus MC Rotterdam, Rotterdam, The Netherlands; 2Institute IRCCS ‘Mondino’, Pavia, Italy; 3Department of Neurology, University of Bari, Bari, Italy; 4Department of Neurology, University of Sa˜o Paulo, Sa˜o Paulo, Brazil; 5Neurological Clinical Research Unit, Institute of Molecular Medicine, Lisbon, Portugal; 6Department of Neurology, University of Insubria, Varese, Italy; 7Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy; 8Department of Neurology, IRCCS ‘Istituto Auxologico Italiano’, Piancavallo, Italy; 9Department
    [Show full text]
  • LRRK2 Biology from Structure to Dysfunction: Research Progresses, but the Themes Remain the Same Daniel C
    Berwick et al. Molecular Neurodegeneration (2019) 14:49 https://doi.org/10.1186/s13024-019-0344-2 REVIEW Open Access LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same Daniel C. Berwick1*†, George R. Heaton2†, Sonia Azeggagh1 and Kirsten Harvey2* Abstract Since the discovery of leucine-rich repeat kinase 2 (LRRK2) as a protein that is likely central to the aetiology of Parkinson’s disease, a considerable amount of work has gone into uncovering its basic cellular function. This effort has led to the implication of LRRK2 in a bewildering range of cell biological processes and pathways, and probable roles in a number of seemingly unrelated medical conditions. In this review we summarise current knowledge of the basic biochemistry and cellular function of LRRK2. Topics covered include the identification of phosphorylation substrates of LRRK2 kinase activity, in particular Rab proteins, and advances in understanding the activation of LRRK2 kinase activity via dimerisation and association with membranes, especially via interaction with Rab29. We also discuss biochemical studies that shed light on the complex LRRK2 GTPase activity, evidence of roles for LRRK2 in a range of cell signalling pathways that are likely cell type specific, and studies linking LRRK2 to the cell biology of organelles. The latter includes the involvement of LRRK2 in autophagy, endocytosis, and processes at the trans- Golgi network, the endoplasmic reticulum and also key microtubule-based cellular structures. We further propose a mechanism linking LRRK2 dimerisation, GTPase function and membrane recruitment with LRRK2 kinase activation by Rab29. Together these data paint a picture of a research field that in many ways is moving forward with great momentum, but in other ways has not changed fundamentally.
    [Show full text]
  • Leucine-Rich Repeat Kinase 2 (LRRK2) Interacts with Parkin, and Mutant LRRK2 Induces Neuronal Degeneration
    Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration Wanli W. Smith*†, Zhong Pei*†, Haibing Jiang*, Darren J. Moore‡§, Yideng Liang*, Andrew B. West‡§, Valina L. Dawson‡§¶, Ted M. Dawson‡§, and Christopher A. Ross*‡ʈ Department of *Psychiatry, Division of Neurobiology, Departments of ‡Neurology and Neuroscience, and ¶Physiology, and §Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 Edited by Solomon H. Snyder, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved October 28, 2005 (received for review September 14, 2005) Parkinson’s disease (PD) is a disorder of movement, cognition, and pathology of cases with LRRK2 mutations is pleomorphic (15, 17). emotion, and it is characterized pathologically by neuronal degen- There are typical features of neuronal loss and gliosis in the eration with Lewy bodies, which are cytoplasmic inclusion bodies substantia nigra. In some cases, there are Lewy bodies and Lewy containing deposits of aggregated proteins. Most PD cases appear neurites, sometimes located diffusely in the brain. In other cases, to be sporadic, but genetic forms of the disease, caused by there are protein deposits, mostly in the cytoplasm, with some mutations in ␣-synuclein, parkin, and other genes, have helped heterogeneity both within and between families. elucidate pathogenesis. Mutations in leucine-rich repeat kinase 2 LRRK2 is a protein with 2,527 aa, including the following several (LRRK2) cause autosomal-dominant Parkinsonism with clinical fea- predicted functional domains: Roc (Ras in complex proteins), COR tures of PD and with pleomorphic pathology including deposits of domain (C-terminal of Roc), a leucine-rich repeat consisting of 12 aggregated protein.
    [Show full text]
  • Mitochondrial E3 Ubiquitin Ligase Parkin: Relationships with Other
    International Journal of Molecular Sciences Review Mitochondrial E3 Ubiquitin Ligase Parkin: Relationships with Other Causal Proteins in Familial Parkinson’s Disease and Its Substrate-Involved Mouse Experimental Models Satoru Torii 1,* , Shuya Kasai 2 , Tatsushi Yoshida 3, Ken-ichi Yasumoto 4 and Shigeomi Shimizu 1 1 Department of Pathological Cell Biology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan; [email protected] 2 Department of Stress Response Science, Center for Advanced Medical Research, Graduate School of Medicine, Hirosaki University, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan; [email protected] 3 Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; [email protected] 4 Department of Molecular and Chemical Life Sciences, Graduate School of Life Sciences, Tohoku University, Sendai 980-8578, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-3-5803-4797; Fax: +81-3-5803-4821 Received: 22 January 2020; Accepted: 9 February 2020; Published: 11 February 2020 Abstract: Parkinson’s disease (PD) is a common neurodegenerative disorder. Recent identification of genes linked to familial forms of PD has revealed that post-translational modifications, such as phosphorylation and ubiquitination of proteins, are key factors in disease pathogenesis. In PD, E3 ubiquitin ligase Parkin and the serine/threonine-protein kinase PTEN-induced kinase 1 (PINK1) mediate the mitophagy pathway for mitochondrial quality control via phosphorylation and ubiquitination of their substrates.
    [Show full text]
  • Structure of LRRK2 in Parkinson's Disease and Model for Microtubule
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2021 February 19. Published in final edited form as: Nature. 2020 December ; 588(7837): 344–349. doi:10.1038/s41586-020-2673-2. Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction CK Deniston1,*, J Salogiannis1,2,*, S Mathea3,*, DM Snead1, I Lahiri1,4, M Matyszewski1, O Donosa2, R Watanabe5,6, J Böhning5,7, AK Shiau8,9, S Knapp3, E Villa5, SL Reck- Peterson1,2,9,#, AE Leschziner1,5,# 1Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla CA, USA 2Howard Hughes Medical Institute, Chevy Chase MD, USA 3Institute of Pharmaceutical Chemistry, Goethe-Universität, Frankfurt, Germany 4Present address: Department of Biological Sciences, Indian Institute of Science Education and Research Mohali, Mohali, Punjab, India 5Division of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla CA, USA 6Present address: La Jolla Institute for Immunology, La Jolla CA, USA 7Present address: Sir William Dunn School of Pathology, Oxford University, Oxford, UK 8Small Molecule Discovery Program, Ludwig Institute for Cancer Research, La Jolla CA, USA 9Division of Biological Sciences, Cell and Developmental Biology Section, University of California San Diego, La Jolla CA, USA Summary Leucine Rich Repeat Kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson’s disease (PD)1 and is also linked to its idiopathic form2. LRRK2 is proposed to function in membrane trafficking3 and co-localizes with microtubules4. Despite LRRK2’s fundamental importance for understanding and treating PD, there is limited structural information on it.
    [Show full text]